Hunan Er-Kang Pharmaceutical Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Qingrong Sun

Chief executive officer

CN¥335.7k

Total compensation

CEO salary percentage	n/a
CEO tenure	5yrs
CEO ownership	n/a
Management average tenure	5yrs
Board average tenure	3.5yrs

Recent management updates

Recent updates

CEO

Qingrong Sun (38 yo)

5yrs

Tenure

CN¥335,700

Compensation

Mr. Qingrong Sun is General Manager of Hunan Er-Kang Pharmaceutical Co., Ltd from November 14, 2019 and serves as Director from November 14, 2022. He joined Hunan Er-Kang Pharmaceutical Co., Ltd. in July 2...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Qingrong Sun	GM & Non-Independent Director	5yrs	CN¥335.70k	no data
Zhao Xun	CFO & Non Independent Director	no data	CN¥389.10k	no data
Xiangyang Shi	Deputy GM & Non Independent Director	no data	CN¥535.10k	no data
Jishun Gu	Deputy GM & Board Secretary	4.7yrs	CN¥514.20k	0.0017% CN¥ 108.0k
Licheng Zhang	Deputy General Manager	no data	CN¥422.70k	no data
Wang Hui	Deputy General Manager	5yrs	CN¥365.30k	no data

5.0yrs

Average Tenure

42.5yo

Average Age

Experienced Management: 300267's management team is seasoned and experienced (5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Qingrong Sun	GM & Non-Independent Director	2yrs	CN¥335.70k	no data
Zhao Xun	CFO & Non Independent Director	5yrs	CN¥389.10k	no data
Xiangyang Shi	Deputy GM & Non Independent Director	6.2yrs	CN¥535.10k	no data
Fangwen Shuai	Chairman of the Board	no data	CN¥512.60k	41.38% CN¥ 2.6b
Junwen Wang	Independent Director	5yrs	CN¥150.00k	no data
Wuzhen Jiang	Independent Director	5yrs	CN¥150.00k	no data
Qing Peng	Chairman of Supervisory Board	3.5yrs	no data	no data
Xue Tan	Independent Director	2yrs	CN¥150.00k	no data
Haiyi Li	Non-Employee Supervisor	2yrs	no data	no data
Hong Wang	Supervisor	2yrs	no data	no data

3.5yrs

Average Tenure

50yo

Average Age

Experienced Board: 300267's board of directors are considered experienced (3.5 years average tenure).

Hunan Er-Kang Pharmaceutical Management

Management criteria checks 3/4

Key information

Recent management updates

Hunan Er-Kang Pharmaceutical Co., Ltd, Annual General Meeting, May 17, 2024

Hunan Er-Kang Pharmaceutical Co., Ltd Announces Executive Changes

Insufficient new directors

High number of new and inexperienced directors

Recent updates

Third quarter 2024 earnings released: CN¥0.015 loss per share (vs CN¥0.006 loss in 3Q 2023)

New major risk - Share price stability

Hunan Er-Kang Pharmaceutical Co., Ltd to Report Q3, 2024 Results on Oct 25, 2024

Second quarter 2024 earnings released: EPS: CN¥0.002 (vs CN¥0.013 in 2Q 2023)

New minor risk - Share price stability

Hunan Er-Kang Pharmaceutical Co., Ltd to Report First Half, 2024 Results on Aug 29, 2024

Hunan Er-Kang Pharmaceutical Co., Ltd, Annual General Meeting, May 17, 2024

Full year 2023 earnings released: CN¥0.095 loss per share (vs CN¥0.022 profit in FY 2022)

Hunan Er-Kang Pharmaceutical Co., Ltd to Report Q1, 2024 Results on Apr 27, 2024

Hunan Er-Kang Pharmaceutical Co., Ltd to Report Fiscal Year 2023 Results on Apr 25, 2024

Third quarter 2023 earnings released

Second quarter 2023 earnings released: EPS: CN¥0.013 (vs CN¥0.004 in 2Q 2022)

Hunan Er-Kang Pharmaceutical Co., Ltd Announces 2022 Final Profit Distribution, Payable on 09 June 2023

Hunan Er-Kang Pharmaceutical Co., Ltd Approves 2022 Profit Distribution Plan

First quarter 2023 earnings released: EPS: CN¥0.013 (vs CN¥0.011 in 1Q 2022)

Hunan Er-Kang Pharmaceutical Co., Ltd Announces Executive Changes

Insufficient new directors

Third quarter 2022 earnings released: EPS: CN¥0.003 (vs CN¥0.026 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.004 (vs CN¥0.024 in 2Q 2021)

Full year 2021 earnings released: CN¥0.38 loss per share (vs CN¥0.098 profit in FY 2020)

High number of new and inexperienced directors

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.026 (vs CN¥0.056 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.024 (vs CN¥0.021 in 2Q 2020)

Hunan Er-Kang Pharmaceutical Co., Ltd Announces 2020 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 09, June 2021

Hunan Er-Kang Pharmaceutical Co., Ltd Approves Final Cash Dividend for the Year 2020

First quarter 2021 earnings released: EPS CN¥0.026 (vs CN¥0.012 in 1Q 2020)

Hunan Er-Kang Pharmaceutical Co., Ltd Proposes Final Cash Dividend for the Year 2020

New 90-day low: CN¥3.79

New 90-day low: CN¥4.17

New 90-day low: CN¥4.62

Third quarter earnings released

Huang Shubiao, Xiao Qingguang, Wu Kaijian, and Huang Linggang completed the acquisition of 95% stake in Guangdong Yueerkang Pharmaceutical Co., Ltd. from Hunan Er-Kang Pharmaceutical Co., Ltd (SZSE:300267).

New 90-day high - CN¥5.23

First half earnings released

Hunan Er-Kang Pharmaceutical Co., Ltd to Report First Half, 2020 Results on Aug 28, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age